BR0307720A - Alkali Metal Addition Stabilized Atorvastatin Formulations, Method for Producing a Pharmaceutical Formulation and Stabilizing Said Formulation - Google Patents
Alkali Metal Addition Stabilized Atorvastatin Formulations, Method for Producing a Pharmaceutical Formulation and Stabilizing Said FormulationInfo
- Publication number
- BR0307720A BR0307720A BR0307720-9A BR0307720A BR0307720A BR 0307720 A BR0307720 A BR 0307720A BR 0307720 A BR0307720 A BR 0307720A BR 0307720 A BR0307720 A BR 0307720A
- Authority
- BR
- Brazil
- Prior art keywords
- atorvastatin
- sodium
- magnesium
- formulation
- alkali metal
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 9
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 9
- 229960005370 atorvastatin Drugs 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 229910052783 alkali metal Inorganic materials 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000000087 stabilizing effect Effects 0.000 title abstract 2
- 150000001340 alkali metals Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- -1 alkali metal salt Chemical class 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 abstract 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 abstract 1
- 240000005369 Alstonia scholaris Species 0.000 abstract 1
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 abstract 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 abstract 1
- 239000004115 Sodium Silicate Substances 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 abstract 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001770 atorvastatin calcium Drugs 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract 1
- 239000000920 calcium hydroxide Substances 0.000 abstract 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 1
- 235000019792 magnesium silicate Nutrition 0.000 abstract 1
- MZUOYVUQORIPHP-MNSAWQCASA-L magnesium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Mg+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 MZUOYVUQORIPHP-MNSAWQCASA-L 0.000 abstract 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 abstract 1
- 235000019799 monosodium phosphate Nutrition 0.000 abstract 1
- 229910001388 sodium aluminate Inorganic materials 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 abstract 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052911 sodium silicate Inorganic materials 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Abstract
"FORMAçõES DE ATORVASTATINA ESTABILIZADAS COM ADIçõES DE METAL ALCALINO, MéTODO PARA PRODUZIR UMA FORMULAçãO FARMACêUTICA E ESTABILIZAR DITA FORMULAçãO". A presente invenção refere-se a uma formulação farmacêutica tendo melhorada biodisponibilidade e bioequivalência que inclui partículas de atorvastatina amorfa e/ou cristalina que têm um tamanho de partícula (d~ 90~) menor que 150 <109>m e um tamanho médio de partícula (d~ 50~) que fica entre aproximadamente 5 e 50 <109>m. A atorvastatina pode ser uma ou mais entre atorvastatina cálcio, atorvastatina magnésio, atorvastatina alumínio, atorvastatina ferro e atorvastatina zinco. As formulações de atorvastatina podem ser estabilizadas pela mistura de atorvastatina com um aditivo de sal de metal alcalino a uma concentração entre aproximadamente 1,2% e menos que 5% peso/peso da formulação. O aditivo de sal de metal alcalino pode ser um ou mais entre carbonato de sódio, bicarbonato de sódio, hidróxido de sódio, silicato de sódio, ortofosfato mono-hidrogênio dissódico, fosfato di-hidrogênio de sódio, fosfato mono-hidrogênio dissódico, fosfato de sódio, aluminato de sódio, carbonato de cálcio, hidróxido de cálcio, carbonato de magnésio, hidróxido de magnésio, silicato de magnésio, aluminato de magnésio e hidróxido de alumínio e magnésio. As formulações de atorvastatina podem ser usadas para tratar condições médicas, incluindo hipercolesterolemia primária, disbetalipoproteinemia e hipercolesterolemia homozigótica familiar."ATORVASTATIN FORMATIONS STABILIZED WITH ALKALINE METAL ADDITIONS, METHOD FOR PRODUCTING PHARMACEUTICAL FORMULATION AND STABILIZING DITA FORMULATION". The present invention relates to a pharmaceutical formulation having improved bioavailability and bioequivalence that includes amorphous and / or crystalline atorvastatin particles having a particle size (d ~ 90 ~) of less than 150 µm and an average particle size ( d ~ 50 ~) which is between about 5 and 50 <109> m. Atorvastatin may be one or more of atorvastatin calcium, atorvastatin magnesium, atorvastatin aluminum, atorvastatin iron and atorvastatin zinc. Atorvastatin formulations may be stabilized by mixing atorvastatin with an alkali metal salt additive at a concentration between approximately 1.2% and less than 5% weight / weight of the formulation. The alkali metal salt additive may be one or more of sodium carbonate, sodium bicarbonate, sodium hydroxide, sodium silicate, disodium monohydrate phosphate, sodium dihydrogen phosphate, disodium monohydrate phosphate, sodium phosphate sodium, sodium aluminate, calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate and magnesium aluminum hydroxide. Atorvastatin formulations may be used to treat medical conditions including primary hypercholesterolaemia, dysbetalipoproteinemia, and familial homozygous hypercholesterolaemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN112DE2002 | 2002-02-14 | ||
| PCT/IB2003/000505 WO2003068191A1 (en) | 2002-02-14 | 2003-02-14 | Formulations of atorvastatin stabilized with alkali metal additions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0307720A true BR0307720A (en) | 2005-01-25 |
Family
ID=27620520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0307720-9A BR0307720A (en) | 2002-02-14 | 2003-02-14 | Alkali Metal Addition Stabilized Atorvastatin Formulations, Method for Producing a Pharmaceutical Formulation and Stabilizing Said Formulation |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030175338A1 (en) |
| EP (1) | EP1336405A1 (en) |
| JP (1) | JP2005522444A (en) |
| KR (1) | KR20040101229A (en) |
| CN (1) | CN1642526A (en) |
| AP (1) | AP2004003112A0 (en) |
| AR (1) | AR038839A1 (en) |
| AU (1) | AU2003245736A1 (en) |
| BR (1) | BR0307720A (en) |
| CA (1) | CA2475722A1 (en) |
| CO (1) | CO5600997A2 (en) |
| EA (1) | EA200401059A1 (en) |
| EC (1) | ECSP045235A (en) |
| HR (1) | HRP20040829A2 (en) |
| IL (1) | IL163550A0 (en) |
| IS (1) | IS7404A (en) |
| MX (1) | MXPA04007905A (en) |
| NO (1) | NO20043790L (en) |
| OA (1) | OA12777A (en) |
| PE (1) | PE20030935A1 (en) |
| PL (1) | PL371337A1 (en) |
| WO (1) | WO2003068191A1 (en) |
| ZA (1) | ZA200406970B (en) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| AU2002247944B2 (en) | 2002-03-18 | 2009-05-21 | Biocon Limited | Amorphous Hmg-CoA reductase inhibitors of desired particle size |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| WO2004094343A1 (en) | 2003-04-22 | 2004-11-04 | Biocon Limited | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ß-KETOESTERS |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| RS20060081A (en) * | 2003-08-05 | 2008-06-05 | Zentiva A.S., | Methods for the stabilization of atorvastatin |
| US7557238B2 (en) | 2003-09-18 | 2009-07-07 | Biocon Limited | Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| AU2005271407A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| CA2576196A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| JP2008514722A (en) * | 2004-09-30 | 2008-05-08 | ドクター レディズ ラボラトリーズ リミテッド | Amorphous atorvastatin calcium |
| AU2005298383A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| US20090208539A1 (en) * | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
| JP2008521878A (en) * | 2004-12-02 | 2008-06-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Pharmaceutical composition of amorphous atorvastatin and process for its production |
| ES2263370B1 (en) * | 2005-02-16 | 2007-12-01 | Ercros Industrial, S.A. | ATORVASTATINA CALCICA STABILIZED AMORFA AND PROCEDURE FOR OBTAINING IT. |
| WO2006123358A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Stabilized atorvastatin-containing formulation |
| DK1879862T3 (en) * | 2005-05-03 | 2011-05-16 | Ranbaxy Lab Ltd | Magnesium salts of HMG-COA reductase inhibitors |
| US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
| WO2007004236A2 (en) * | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| JP2009515816A (en) * | 2005-08-04 | 2009-04-16 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | Novel formulations comprising fenofibrate and statins and related methods of treatment |
| AU2006313009B2 (en) * | 2005-11-10 | 2013-10-24 | Alphapharm Pty Ltd | Process to control particle size |
| CA2628716C (en) * | 2005-11-10 | 2016-09-27 | Alphapharm Pty Ltd | Process to control particle size |
| US8084488B2 (en) | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
| US20090111997A1 (en) * | 2005-11-23 | 2009-04-30 | Aaron Cote | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals |
| JP2009517459A (en) * | 2005-11-29 | 2009-04-30 | バイオコン・リミテッド | [R- (R *, R *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- Polymorph of 1H-pyrrole-1-heptanoic acid magnesium salt (2: 1) |
| EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
| US7772273B2 (en) * | 2006-02-10 | 2010-08-10 | Lifecycle Pharma A/S | Stabilized atorvastatin |
| WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| SI22255A (en) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | New polymorphs of statine salts and their application in pharmaceutical formulations |
| CN101516842A (en) | 2006-05-11 | 2009-08-26 | 百康有限公司 | A crystalline form B4 of atorvastatin magnesium and a process thereof |
| US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
| HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
| US20100029743A1 (en) * | 2006-09-27 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| JP2010513324A (en) | 2006-12-21 | 2010-04-30 | アルファファーム ピーティーワイ リミテッド | Pharmaceutical compounds and pharmaceutical compositions |
| IS8587A (en) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin pharmaceutical combination |
| CN101224205B (en) * | 2007-01-20 | 2010-11-17 | 石药集团中奇制药技术（石家庄）有限公司 | Composition of atorvastatin and levorotatory amlodipine and preparing method thereof |
| IS8607A (en) * | 2007-02-09 | 2008-08-10 | Actavis Group Hf. | Stable atorvastatin combination |
| CZ300047B6 (en) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Pharmaceutical composition containing atorvastatin as active substance |
| NZ579736A (en) * | 2007-04-13 | 2012-02-24 | Nicox Sa | Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester |
| US20110142883A1 (en) * | 2007-07-20 | 2011-06-16 | Actavis Group Ptc Ehf | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| US20110064816A1 (en) * | 2008-05-13 | 2011-03-17 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
| US20110082071A1 (en) * | 2008-05-15 | 2011-04-07 | Amal Elabbadi | Delivery system for an active ingredient |
| EP2127628A1 (en) | 2008-05-27 | 2009-12-02 | Ranbaxy Laboratories Limited | Unit dose pack |
| CA2767560A1 (en) * | 2008-07-25 | 2010-01-28 | Alphapharm Pty Ltd | Atovaquone with a particle size diameter range (d90) of greater than 3um to about 10um |
| EP2341773A4 (en) * | 2008-09-24 | 2012-03-07 | Merck Sharp & Dohme | Pharmaceutical compositions of atorvastatin |
| WO2010038688A1 (en) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | Particulate pharmaceutical composition for oral administration of atorvastatin |
| CN101791297B (en) * | 2010-02-10 | 2012-03-28 | 中国药科大学 | Atorvastatin calcium oral disintegrating tablet and preparation method thereof |
| JP5614445B2 (en) * | 2010-03-29 | 2014-10-29 | アステラス製薬株式会社 | Particulate pharmaceutical composition for oral administration |
| JP5534004B2 (en) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | Orally disintegrating tablets |
| US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| EP2566465A2 (en) * | 2010-05-04 | 2013-03-13 | Mahmut Bilgic | Stable rosuvastatin formulations |
| HUP1000299A2 (en) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation |
| WO2011154009A1 (en) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprising an active principle in an amorphous form and a porous adsorbent material |
| US20120165386A1 (en) * | 2010-12-27 | 2012-06-28 | Ranbaxy Laboratories Limited | Stable oral pharmaceutial composition of atorvastatin |
| RU2014124118A (en) | 2011-11-15 | 2015-12-27 | Др. Редди'С Лабораторис Лтд. | PHARMACEUTICALS, INCLUDING ATORVASTATIN AND GLIMEPIRIDE |
| CN104069502B (en) * | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | Compound skeleton material and its pharmaceutical composition |
| JP6507808B2 (en) * | 2015-04-09 | 2019-05-08 | ニプロ株式会社 | Oral disintegrating tablet |
| WO2017106130A1 (en) * | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Process for preparing pharmaceutical compositions |
| EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| CN106420645A (en) * | 2016-11-24 | 2017-02-22 | 浙江新东港药业股份有限公司 | Calcium tablet containing atorvastatin and preparation method |
| CN108421045B (en) * | 2018-04-02 | 2021-09-24 | 北京海晶生物医药科技有限公司 | Atorvastatin calcium composition, preparation and preparation method thereof |
| CN109044989A (en) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | A kind of atorvastatin calcium capsule preparation and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| ATE178794T1 (en) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | STABILIZED ORAL COMPOSITION CONTAINING THE COMPOUND CI-981 AND METHOD |
| SI20109A (en) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stable pharmaceutical formulation |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| SI20848A (en) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Pharmaceutical formulation containing atorvastatin calcium |
-
2003
- 2003-02-14 CN CNA038070286A patent/CN1642526A/en active Pending
- 2003-02-14 EA EA200401059A patent/EA200401059A1/en unknown
- 2003-02-14 IL IL16355003A patent/IL163550A0/en unknown
- 2003-02-14 MX MXPA04007905A patent/MXPA04007905A/en not_active Application Discontinuation
- 2003-02-14 JP JP2003567375A patent/JP2005522444A/en active Pending
- 2003-02-14 US US10/367,552 patent/US20030175338A1/en not_active Abandoned
- 2003-02-14 KR KR10-2004-7012657A patent/KR20040101229A/en not_active Application Discontinuation
- 2003-02-14 AU AU2003245736A patent/AU2003245736A1/en not_active Abandoned
- 2003-02-14 AP APAP/P/2004/003112A patent/AP2004003112A0/en unknown
- 2003-02-14 CA CA002475722A patent/CA2475722A1/en not_active Abandoned
- 2003-02-14 PE PE2003000161A patent/PE20030935A1/en not_active Application Discontinuation
- 2003-02-14 EP EP03405088A patent/EP1336405A1/en not_active Withdrawn
- 2003-02-14 AR ARP030100494A patent/AR038839A1/en not_active Application Discontinuation
- 2003-02-14 PL PL03371337A patent/PL371337A1/en not_active Application Discontinuation
- 2003-02-14 BR BR0307720-9A patent/BR0307720A/en not_active IP Right Cessation
- 2003-02-14 WO PCT/IB2003/000505 patent/WO2003068191A1/en active Application Filing
- 2003-02-14 OA OA1200400219A patent/OA12777A/en unknown
-
2004
- 2004-08-13 CO CO04079402A patent/CO5600997A2/en not_active Application Discontinuation
- 2004-08-13 IS IS7404A patent/IS7404A/en unknown
- 2004-08-16 EC EC2004005235A patent/ECSP045235A/en unknown
- 2004-09-01 ZA ZA200406970A patent/ZA200406970B/en unknown
- 2004-09-09 NO NO20043790A patent/NO20043790L/en unknown
- 2004-09-13 HR HR20040829A patent/HRP20040829A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1336405A1 (en) | 2003-08-20 |
| CA2475722A1 (en) | 2003-08-21 |
| EA200401059A1 (en) | 2005-02-24 |
| US20030175338A1 (en) | 2003-09-18 |
| JP2005522444A (en) | 2005-07-28 |
| ZA200406970B (en) | 2005-06-20 |
| AP2004003112A0 (en) | 2004-09-30 |
| PL371337A1 (en) | 2005-06-13 |
| OA12777A (en) | 2006-07-06 |
| CO5600997A2 (en) | 2006-01-31 |
| NO20043790L (en) | 2004-11-08 |
| WO2003068191A1 (en) | 2003-08-21 |
| AU2003245736A1 (en) | 2003-09-04 |
| ECSP045235A (en) | 2004-09-28 |
| HRP20040829A2 (en) | 2006-07-31 |
| PE20030935A1 (en) | 2003-10-30 |
| IL163550A0 (en) | 2005-12-18 |
| KR20040101229A (en) | 2004-12-02 |
| MXPA04007905A (en) | 2004-11-26 |
| AR038839A1 (en) | 2005-01-26 |
| IS7404A (en) | 2004-08-13 |
| CN1642526A (en) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307720A (en) | Alkali Metal Addition Stabilized Atorvastatin Formulations, Method for Producing a Pharmaceutical Formulation and Stabilizing Said Formulation | |
| JP2005522444A5 (en) | ||
| US4296103A (en) | Stabilized solution of chlorine oxides | |
| FI121589B (en) | Pharmaceutical composition comprising (E) -7 [4- (4-fluorophenyl) -6-isopropyl-2 [methyl (methylsulfonyl) amino] pyrimidin-5-yl] - (3R, 5S) -3,5-dihydroxy-6 heptenoic acid | |
| SK282991B6 (en) | Pharmaceutical composition stabilised with a basic agent | |
| SA01220291A (en) | Stable oral c1-981 formulation and process of preparing same | |
| BR9802487A (en) | Compositions of simethicone / anhydrous calcium phosphate. | |
| GR3031135T3 (en) | Compositions containing S(+)-Ibuprofen. | |
| RU2005115855A (en) | COMPOSITION OF TRAMADOL PROLONGED BY RELEASE WITH 24 HOUR ACTION | |
| SI1499297T1 (en) | Pharmaceutical formulation comprising atorvastatin calcium | |
| SK283936B6 (en) | Pharmaceutical moxifloxacin preparation | |
| BR9611815A (en) | Chewing tablet with effervescent action | |
| MY109531A (en) | Effervescent antacid | |
| UA83328C2 (en) | Formulation for prevention of oral cavity diseases | |
| MXPA03011737A (en) | Chewing gum to control malodorous breath. | |
| AU2908189A (en) | Aqueous preparation based on mineral salts and acetic acid for the prevention and treatment of viral diseases | |
| ATE163265T1 (en) | ASSOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE DERIVATIVES AND CALCIUM SALTS | |
| CA2239331C (en) | Pharmaceutical tablets comprising cefuroxime axetil | |
| CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
| CA2122908C (en) | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones | |
| KR101302243B1 (en) | Pharmaceutical composition comprising Rosuvastatin or the salt thereof | |
| WO2003097039A1 (en) | Stable dosage forms comprising atorvastatin calcium | |
| JPS649928A (en) | Bathing composition | |
| JP2003002829A (en) | Pharmaceutical composition | |
| KR960003733A (en) | Antacid formulations with improved safety profile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A., 6A., E 7A. ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |